Chapter 32 — Hypothalamic Pharmacology — Module 2 — GnRH Analogs in Clinical Practice
1. A 58-year-old man with newly diagnosed metastatic prostate cancer is started on leuprolide depot. His oncologist explains that testosterone suppression will be sustained because the drug maintains continuous, non-pulsatile occupancy of gonadotropin-releasing hormone receptors (GnRHR) on pituitary gonadotrophs. Which of the following best describes the molecular mechanism by which prolonged GnRH agonist exposure reduces GnRHR surface density to produce medical castration?
A) GnRHR undergoes rapid clathrin-mediated internalization via beta-arrestin recruitment within minutes of agonist binding, permanently degrading receptors in lysosomes
B) GnRHR is internalized via a clathrin-independent, dynamin-dependent pathway that reduces surface receptor density by 80 to 95% over days to weeks, removing receptors from the cell surface and eliminating gonadotropin stimulation
C) GnRHR downregulation occurs exclusively through PKC-mediated phosphorylation that uncouples the receptor from Gq/11 signaling without any reduction in surface receptor number
D) GnRHR internalization is triggered by FSH-mediated negative feedback from the gonads rather than by continuous agonist occupancy of the receptor itself
E) GnRHR surface density is reduced by transcriptional suppression of the GnRHR gene, a process that requires at least 8 weeks of continuous agonist exposure before castrate testosterone levels are achieved
ANSWER: B
Rationale:
Prolonged, non-pulsatile GnRH agonist exposure reduces pituitary GnRHR surface density through a clathrin-independent, dynamin-dependent internalization pathway. This process unfolds over days to weeks and removes 80 to 95% of surface receptors, eliminating the capacity of the gonadotroph to respond to GnRH and thereby producing the sustained LH and FSH suppression that underlies medical castration. This mechanism is pharmacodynamically distinctive: because the GnRHR uniquely lacks an intracellular carboxyl-terminal tail found on most other G protein-coupled receptors (GPCRs), the receptor cannot engage the classical clathrin/beta-arrestin internalization pathway used by most GPCRs, making the dynamin-dependent route the dominant mechanism for GnRHR trafficking.
Option A: Option A is incorrect because GnRHR internalization is clathrin-independent; classical clathrin/beta-arrestin recruitment describes the pathway for most other GPCRs but not GnRHR.
Option C: Option C is incorrect because PKC-mediated receptor uncoupling is an early (phase one) desensitization event occurring within hours; it does not produce the surface receptor loss responsible for sustained medical castration, which requires the internalization phase described in option B.
Option D: Option D is incorrect because GnRHR downregulation is driven directly by continuous agonist occupancy of the receptor, not by gonadal hormonal feedback to the pituitary; FSH-mediated gonadal feedback operates via separate hypothalamic and pituitary feedback circuits.
Option E: Option E is incorrect because transcriptional suppression of GnRHR gene expression is not the primary mechanism of downregulation; surface receptor loss through internalization occurs over days to weeks and does not require an 8-week delay before castrate testosterone levels are achieved — castrate levels are typically reached within 3 to 4 weeks of depot initiation.
2. A 67-year-old man with high-volume metastatic prostate cancer and lumbar vertebral metastases is about to begin androgen deprivation therapy. His urologist is deciding between leuprolide depot and degarelix. Regarding the testosterone flare that occurs with GnRH agonist initiation, which of the following best explains the intracellular signaling sequence responsible for the initial LH surge?
A) GnRH agonist binding activates Gs protein, increasing cyclic AMP and activating protein kinase A, which drives LH secretion during the first 1 to 2 weeks of therapy
B) The initial LH surge results from agonist-induced receptor desensitization that transiently blocks FSH secretion while amplifying LH release through a receptor isoform-selective mechanism
C) GnRH agonist binding triggers receptor dimerization and recruitment of JAK2 kinase, which phosphorylates STAT5 and activates transcription of the LH beta-subunit gene within 24 hours
D) GnRH agonist binding activates Gq/11, which stimulates phospholipase C beta to generate IP3 and DAG, mobilizing intracellular calcium and activating PKC, driving an LH and FSH surge that elevates testosterone 50 to 80% above baseline for 1 to 2 weeks
E) The initial LH surge reflects rebound secretion from pituitary gonadotrophs that were tonically inhibited by prior continuous endogenous GnRH exposure, which is released when the agonist competitively displaces GnRH from the receptor
ANSWER: D
Rationale:
GnRH agonist binding at agonist initiation is pharmacologically indistinguishable from an endogenous GnRH pulse. The GnRHR couples to Gq/11 protein, which activates phospholipase C beta (PLC-beta), generating the second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes calcium from the endoplasmic reticulum, and DAG activates protein kinase C (PKC); together, these signals drive exocytosis of stored LH and FSH from gonadotrophs. This produces a substantial LH surge and resultant testosterone elevation of 50 to 80% above baseline, lasting 1 to 2 weeks, which constitutes the clinical testosterone flare. In patients with vertebral metastases, this flare carries risk of spinal cord compression, making degarelix or relugolix — which bypass flare entirely — the preferred choice in this clinical scenario.
Option A: Option A is incorrect because GnRHR does not couple to Gs protein; the relevant G protein for GnRHR signaling is Gq/11, not Gs. Cyclic AMP and protein kinase A are not the mediators of the GnRH-induced LH surge.
Option B: Option B is incorrect because the initial LH surge is not produced by a receptor desensitization mechanism or by selective FSH suppression; both LH and FSH are released during the flare, driven by the receptor activation cascade described in option D.
Option C: Option C is incorrect because GnRHR does not signal through JAK2/STAT5 pathways; JAK-STAT signaling characterizes cytokine and growth hormone receptor pathways, not GnRH receptor signaling.
Option E: Option E is incorrect because endogenous GnRH stimulates the pituitary in a pulsatile pattern; there is no tonic inhibitory GnRH effect on gonadotrophs. The flare reflects agonist-driven stimulation, not rebound from prior inhibition.
3. A 72-year-old man with metastatic castration-sensitive prostate cancer and multiple lumbar vertebral metastases is being started on leuprolide 22.5 mg IM depot (3-month formulation). His oncologist decides to add flare prevention coverage. Which of the following most accurately describes the correct pharmacological approach and rationale for flare prevention in this patient?
A) Bicalutamide 50 mg daily should be initiated 7 to 14 days before the first leuprolide injection and continued for 4 weeks, blocking androgen receptor activation at the prostate during the testosterone surge to prevent disease flare, spinal cord compression, and worsening bone pain
B) Flutamide 250 mg three times daily should be started on the same day as the first leuprolide injection and continued for 8 weeks to ensure complete anti-androgen coverage throughout the full duration of the testosterone surge
C) An anti-androgen is not required when using a 3-month depot formulation because the slower initial drug release from PLGA microspheres attenuates the initial testosterone surge compared with the 1-month depot
D) Anti-androgen co-administration should be avoided because combined androgen blockade with continuous GnRH agonist plus anti-androgen is associated with substantially greater survival benefit and is now standard of care for all patients with metastatic disease
E) Cyproterone acetate 200 mg daily is the preferred anti-androgen for flare prevention because its steroidal structure enables progestogenic activity that further suppresses LH secretion, accelerating the onset of medical castration
ANSWER: A
Rationale:
The standard approach to testosterone flare prevention with GnRH agonist initiation is bicalutamide 50 mg daily, begun 7 to 14 days before the first depot injection and continued for approximately 4 weeks. This timing ensures androgen receptor (AR) blockade is established before the testosterone surge begins. Bicalutamide competitively blocks the AR at the prostate and other target tissues, preventing testosterone and dihydrotestosterone (DHT) from driving tumor growth, bone pain, and risk of spinal cord compression during the 1 to 2 weeks of elevated testosterone. In this patient with vertebral metastases, the flare risk is particularly high, and anti-androgen coverage is mandatory.
Option B: Option B is incorrect on both timing and duration: flutamide should be started before, not on the day of, the first injection to ensure AR blockade is present when the flare begins; the recommended coverage period is approximately 4 weeks, not 8 weeks. Flutamide is also a less commonly used choice due to three-times-daily dosing and a less favorable tolerability profile compared with bicalutamide.
Option C: Option C is incorrect because all GnRH agonist depot formulations, including the 3-month depot, produce a testosterone flare of similar magnitude; the PLGA microsphere release kinetics maintain sustained plasma drug concentrations but do not eliminate the initial receptor activation phase responsible for the LH surge.
Option D: Option D is incorrect because combined androgen blockade (continuous GnRH agonist plus continuous anti-androgen) provides only marginal progression-free survival benefit over agonist monotherapy in most analyses and substantially increases adverse effects; it is not recommended as a universal standard. Anti-androgen is used for flare prevention only at agonist initiation, not continued indefinitely.
Option E: Option E is incorrect because cyproterone acetate is not the preferred agent for flare prevention in North American practice; while its progestogenic properties do suppress LH somewhat, it is associated with cardiovascular adverse effects and is not favored over bicalutamide for this indication.
4. A pharmacist is counseling a resident on the formulation differences between two leuprolide acetate products available for androgen deprivation therapy: Lupron Depot and Eligard. Which of the following best distinguishes the drug delivery technology used in each formulation?
A) Lupron Depot uses an atrigel polymer system injected subcutaneously, while Eligard uses poly(lactic-co-glycolic acid) microspheres for intramuscular injection; the two formulations are interchangeable in clinical practice
B) Both Lupron Depot and Eligard use identical PLGA microsphere technology and differ only in the leuprolide acetate salt form used, which affects dissolution rate but not the route of administration or pharmacokinetic profile
C) Lupron Depot uses poly(lactic-co-glycolic acid) microspheres for intramuscular injection that release leuprolide through slow polymer hydrolysis, while Eligard uses an atrigel polymer delivery system injected subcutaneously that gels upon contact with tissue fluid at the injection site
D) Lupron Depot is a preloaded biodegradable rod-shaped implant placed subcutaneously in the anterior abdominal wall using a trocar device, while Eligard requires mixing of polymer and drug at the time of injection before intramuscular administration
E) Eligard provides superior testosterone suppression compared with Lupron Depot because the atrigel system achieves higher peak plasma leuprolide concentrations during the first 48 hours, more rapidly downregulating GnRHR surface expression
ANSWER: C
Rationale:
Lupron Depot uses poly(lactic-co-glycolic acid) (PLGA) microsphere technology in which leuprolide acetate is encapsulated within biodegradable polymer microspheres and suspended for intramuscular (IM) injection. Upon IM injection, the microspheres undergo slow hydrolysis at body temperature, releasing leuprolide at a controlled rate over the dosing interval. Available Lupron Depot formulations provide 1-, 3-, 4-, and 6-month dosing intervals. Eligard, by contrast, uses the atrigel polymer delivery system: the drug and polymer are supplied in separate syringes and mixed at the point of care; when the mixture is injected subcutaneously (SC), it contacts tissue fluid, undergoes phase transition, and gels in situ, forming a sustained-release depot at the injection site. Eligard is available in 1-, 3-, and 6-month SC formulations. Both systems maintain sustained plasma leuprolide concentrations sufficient to drive GnRHR downregulation, but the formulation technologies, injection routes, and clinical preparation differ meaningfully.
Option A: Option A is incorrect because it reverses the formulation assignments: Lupron Depot uses PLGA microspheres for IM injection, not atrigel SC, and the two formulations are not pharmacologically interchangeable without accounting for route and preparation differences.
Option B: Option B is incorrect because Lupron Depot and Eligard use entirely different drug delivery technologies — PLGA microspheres versus atrigel polymer — and differ in injection route (IM versus SC), not merely in salt form.
Option D: Option D is incorrect because it describes goserelin (Zoladex), which is formulated as a preloaded biodegradable rod-shaped implant placed SC in the abdominal wall with a trocar device; neither Lupron Depot nor Eligard uses this technology.
Option E: Option E is incorrect because no robust clinical evidence establishes superior testosterone suppression for Eligard compared with Lupron Depot based on higher early peak concentrations; the pharmacodynamic endpoint — sustained castrate testosterone — is equivalent across formulations when administered correctly.
5. A 64-year-old man with locally advanced prostate cancer is being switched from leuprolide microsphere depot to goserelin acetate (Zoladex). The nurse asks the supervising physician about important administration and pharmacokinetic differences for goserelin. Which of the following statements about goserelin formulation, administration, and elimination is correct?
A) Goserelin is formulated as a lyophilized powder in a prefilled syringe that must be reconstituted with sterile diluent and injected intramuscularly into the gluteus; failure to reconstitute properly results in dose loss
B) Goserelin is available only as a 1-month formulation and must be injected into the deltoid muscle; the 3-month formulation was withdrawn from the US market due to inconsistent testosterone suppression in clinical trials
C) Goserelin is eliminated primarily by hepatic CYP3A4 metabolism, requiring dose reduction in patients with significant hepatic impairment; renal function has no meaningful impact on its pharmacokinetics
D) Goserelin is prepared by mixing drug and polymer in two separate syringes at the bedside and injected subcutaneously into the thigh, where it gels in situ and provides controlled drug release over the designated interval
E) Goserelin is formulated as a preloaded biodegradable rod-shaped implant in a glycolic acid-lactic acid copolymer matrix, placed subcutaneously in the anterior abdominal wall using a trocar-equipped device, with approximately 90% renal elimination
ANSWER: E
Rationale:
Goserelin acetate (Zoladex) is formulated as a preloaded, rod-shaped biodegradable implant containing the drug in a glycolic acid-lactic acid copolymer matrix. It is placed subcutaneously in the anterior abdominal wall using a specialized trocar-equipped device — no reconstitution is required, distinguishing it from leuprolide microsphere depots. The 1-month formulation contains 3.6 mg and the 3-month formulation contains 10.8 mg. The implant matrix degrades progressively, releasing goserelin over the designated interval. Importantly, proper subcutaneous (not intramuscular) placement is essential: intramuscular implantation prevents controlled polymer degradation and can result in unpredictable pharmacokinetics. Goserelin is eliminated approximately 90% renally; mild renal impairment has minimal impact on clinical efficacy, and dose adjustment is not typically required.
Option A: Option A is incorrect because goserelin does not require reconstitution; it is a preloaded solid implant, not a lyophilized powder, and is not injected intramuscularly.
Option B: Option B is incorrect because both 1-month (3.6 mg) and 3-month (10.8 mg) goserelin formulations are clinically available and approved; neither has been withdrawn from the US market.
Option C: Option C is incorrect because goserelin is eliminated primarily renally, not via hepatic CYP3A4 metabolism; hepatic metabolism is not the dominant elimination pathway, and renal function is the relevant pharmacokinetic consideration.
Option D: Option D is incorrect because it describes the atrigel polymer system used by Eligard (leuprolide), not goserelin; goserelin does not involve bedside drug-polymer mixing and is not injected into the thigh.
6. A 69-year-old man with metastatic prostate cancer has been on leuprolide 22.5 mg IM depot every 3 months for 18 months. His most recent PSA has risen from 0.4 to 3.8 ng/mL. A serum testosterone drawn the morning before his scheduled depot injection is 74 ng/dL. His injection technique has not been evaluated. Which of the following best describes the likely explanation and appropriate clinical response?
A) A testosterone of 74 ng/dL indicates primary resistance to GnRH agonist therapy due to acquired mutations in the GnRHR gene and should prompt immediate referral for genetic testing and consideration of surgical orchiectomy
B) Non-castrate testosterone on depot agonist therapy is likely, possibly due to depot delivery failure from incorrect injection technique or injection site fibrosis reducing absorption; the appropriate response includes verifying injection technique, rotating injection sites, and considering a switch to an antagonist such as degarelix or relugolix
C) A testosterone of 74 ng/dL is within the expected pharmacokinetic nadir range immediately before a scheduled injection, represents end-of-dose variation that does not require any change in therapy, and the PSA rise is unrelated to testosterone levels
D) This testosterone level indicates secondary failure from pituitary resistance to GnRH agonist suppression and requires addition of a second GnRH agonist at a higher dose to restore adequate receptor downregulation
E) Non-castrate testosterone on therapy is caused exclusively by patient non-compliance with oral anti-androgen co-administration; restoring bicalutamide to the regimen will return testosterone to castrate levels within 1 to 2 weeks
ANSWER: B
Rationale:
Non-castrate testosterone on depot agonist therapy — defined as serum testosterone above 50 ng/dL despite ongoing treatment — occurs in approximately 4 to 13% of patients depending on assay and population studied. This patient's testosterone of 74 ng/dL with a rising PSA signals a clinically significant loss of castrate suppression. The most common causes are depot delivery failure (incorrect injection technique placing drug IM when SC is intended or vice versa, preventing controlled polymer release), injection site fibrosis from repeated injections impairing drug absorption, or end-of-dose escape (testosterone rising before the next scheduled injection as the depot nears exhaustion). The appropriate clinical response is to evaluate and correct injection technique, rotate injection sites, and consider switching to a GnRH antagonist (degarelix or relugolix), which maintains castrate testosterone levels more consistently in some comparative studies. Recent guidelines also suggest that a castration target below 20 ng/dL (rather than the traditional 50 ng/dL) may improve oncological outcomes.
Option A: Option A is incorrect because acquired GnRHR mutations causing primary resistance are extremely rare and are not the appropriate first consideration when technical causes have not been evaluated; genetic testing is not indicated as an initial step.
Option C: Option C is incorrect because testosterone of 74 ng/dL is not within acceptable castrate range by any definition (castrate: below 50 ng/dL traditionally, below 20 ng/dL by newer criteria); attributing the PSA rise to an unrelated cause without addressing the non-castrate testosterone is clinically inappropriate.
Option D: Option D is incorrect because there is no recognized clinical entity of pituitary resistance to GnRH agonist suppression requiring higher doses of the same drug class; the mechanism of non-castrate testosterone is pharmacokinetic (delivery failure), not receptor resistance.
Option E: Option E is incorrect because anti-androgen therapy (bicalutamide) blocks the androgen receptor but does not lower serum testosterone levels; non-castrate testosterone is a pharmacokinetic failure of the GnRH agonist, not an anti-androgen co-administration issue.
7. A 70-year-old man with bulky high-risk prostate cancer, a PSA of 180 ng/mL, and multiple vertebral metastases requires immediate androgen deprivation. His cardiologist notes a baseline QTc of 458 ms. Which of the following best describes the pharmacodynamic mechanism by which degarelix achieves testosterone suppression and why it is preferred over a GnRH agonist in this clinical scenario?
A) Degarelix acts as a partial agonist at GnRHR, producing low-level receptor activation insufficient to drive LH secretion while occupying the receptor and blocking full agonist binding; testosterone falls gradually over 3 to 4 weeks without any initial surge
B) Degarelix competitively inhibits gonadotropin secretion at the level of pituitary FSH receptors rather than GnRHR, avoiding any interaction with the hypothalamic GnRH signaling pathway and thus eliminating the risk of testosterone flare entirely
C) Degarelix irreversibly blocks GnRHR through covalent bond formation, producing permanent receptor inactivation that prevents LH secretion for the duration of the monthly injection interval; testosterone reaches castrate levels within 1 week
D) Degarelix competitively and reversibly blocks GnRHR on pituitary gonadotrophs, immediately suppressing LH and FSH without any receptor activation, achieving castrate testosterone levels in more than 96% of patients within 3 days and producing no testosterone flare
E) Degarelix acts downstream of GnRHR by inhibiting the Gq/11-PLC-beta signaling cascade within gonadotrophs, preventing IP3 generation and calcium mobilization required for LH secretion, with testosterone reaching castrate levels over 1 to 2 weeks
ANSWER: D
Rationale:
Degarelix is a competitive, reversible GnRH receptor antagonist. It binds GnRHR on pituitary gonadotrophs and blocks receptor occupancy by endogenous GnRH without any initial receptor activation — there is no Gq/11 coupling, no PLC-beta stimulation, no IP3/calcium mobilization, and no LH surge. The result is immediate suppression of LH and FSH secretion and rapid testosterone decline. In clinical studies, degarelix achieves castrate testosterone levels (below 50 ng/dL) in more than 96% of patients within 3 days of the loading dose (240 mg given as two 120 mg SC injections on day 1). This contrasts sharply with GnRH agonist depots, which take 3 to 4 weeks to reach castrate levels and produce a 1- to 2-week testosterone flare that is dangerous in this patient with vertebral metastases. The absence of flare makes degarelix (or oral relugolix) the preferred choice when rapid testosterone suppression is required or when testosterone flare poses a risk of spinal cord compression or worsening bone pain.
Option A: Option A is incorrect because degarelix is not a partial agonist; it is a full competitive antagonist producing no receptor activation whatsoever. Testosterone does not fall gradually over 3 to 4 weeks — it falls within days, which is the pharmacodynamic advantage of the antagonist class.
Option B: Option B is incorrect because degarelix acts at GnRHR on pituitary gonadotrophs, not at FSH receptors; FSH receptors are located on gonadal cells, not on pituitary gonadotrophs.
Option C: Option C is incorrect because degarelix does not bind covalently to GnRHR; it acts through reversible competitive antagonism, and permanent receptor inactivation is not its mechanism.
Option E: Option E is incorrect because degarelix acts at the receptor level, preventing GnRH from binding and initiating the signaling cascade; it does not enter gonadotroph cells to inhibit intracellular Gq/11-PLC-beta signaling downstream of the receptor.
8. A 66-year-old man with advanced prostate cancer has been receiving degarelix 80 mg SC monthly for 4 months. He reports pain, redness, and a firm nodule at injection sites that persists for 1 to 2 weeks after each injection. His testosterone is 18 ng/dL. Which of the following best characterizes this adverse effect and its mechanism?
A) Injection site reactions including pain, erythema, and nodule formation occur in approximately 35 to 40% of patients receiving degarelix, substantially more frequently than with IM leuprolide or goserelin, and result from the depot-gel mechanism in which the drug aggregates into a hydrogel at the SC injection site
B) This presentation is consistent with a type I hypersensitivity reaction mediated by IgE antibodies directed against the degarelix peptide backbone; skin testing should be performed before the next injection and the patient should be switched to a GnRH agonist
C) Injection site reactions with degarelix are caused by complement activation by the peptide structure, occurring in approximately 0.9% of patients, and carry a risk of progression to anaphylaxis; the drug should be discontinued immediately
D) These findings represent systemic injection site reactions caused by testosterone flare-induced tissue inflammation and will resolve once medical castration is fully established, typically after 2 to 3 monthly injections
E) Injection site nodule formation with degarelix indicates subcutaneous fibrosis from the polymer carrier vehicle that permanently impairs drug absorption; switching to IM injection technique will resolve absorption failure and restore testosterone suppression
ANSWER: A
Rationale:
Injection site reactions — including pain, erythema, swelling, and palpable nodule formation — are the most clinically significant limitation of degarelix compared with IM GnRH agonist depots, occurring in approximately 35 to 40% of patients. The mechanism is specific to the degarelix depot-gel: degarelix is a decapeptide that, when injected subcutaneously in aqueous tissue environments, aggregates into a hydrogel at the injection site. This in situ gel formation is the mechanism of sustained drug release but also the source of local tissue reactions — the hydrogel is a foreign body-like depot that provokes a local inflammatory response, producing pain, erythema, and palpable induration or nodule. These reactions are generally self-limited, manageable with warm compresses, and should be addressed by rotating injection sites. They do not indicate drug failure; this patient's testosterone of 18 ng/dL confirms ongoing effective castration.
Option B: Option B is incorrect because the injection site reactions of degarelix are not IgE-mediated type I hypersensitivity; they are local reactions to the depot gel, not systemic allergic responses. Switching to a GnRH agonist for this reason is not indicated.
Option C: Option C is incorrect because complement activation causing anaphylaxis was the problem with abarelix, not degarelix. Degarelix was specifically developed to minimize the histamine-releasing potential that caused abarelix's withdrawal; the 35 to 40% injection site reaction rate with degarelix is a local phenomenon, not anaphylaxis.
Option D: Option D is incorrect because these injection site reactions are not caused by testosterone flare; degarelix produces no testosterone flare whatsoever, and the reactions occur consistently with every monthly injection, not only during the initial treatment period.
Option E: Option E is incorrect because degarelix is not formulated with a polymer carrier vehicle; it forms its own depot gel from the peptide itself. Additionally, degarelix is dosed SC by design, not IM; switching to IM administration is not appropriate and would alter the controlled-release mechanism.
9. A resident asks why abarelix, the first injectable GnRH antagonist approved for prostate cancer, was withdrawn from the US market. Which of the following best describes the safety concern that led to its withdrawal and the pharmacological basis of that concern?
A) Abarelix was withdrawn because it produced a more severe testosterone flare than GnRH agonist depots due to partial agonist activity at GnRHR, causing unacceptable rates of spinal cord compression and disease progression in men with vertebral metastases
B) Abarelix was withdrawn because it caused progressive pituitary gonadotroph toxicity, leading to permanent hypogonadism in approximately 12% of patients even after drug discontinuation, a liability not shared by later antagonists
C) Abarelix was withdrawn because it caused serious systemic allergic reactions, including anaphylaxis, in approximately 0.9% of patients, attributed to complement activation by the peptide backbone structure; degarelix was subsequently developed with a modified peptide structure substantially reducing histamine-releasing activity
D) Abarelix was withdrawn because of unacceptable rates of QT interval prolongation exceeding those of GnRH agonists due to a direct cardiac ion channel effect of the peptide backbone independent of testosterone suppression
E) Abarelix was withdrawn because it required daily SC injections for the first 2 weeks before monthly dosing could begin, and patient compliance with the induction regimen was so poor that castrate testosterone levels were rarely achieved in clinical practice
ANSWER: C
Rationale:
Abarelix was the first injectable GnRH receptor antagonist approved for prostate cancer in the United States. It was withdrawn from the market because of a significant rate of serious systemic allergic reactions, including anaphylaxis, occurring in approximately 0.9% of patients. These reactions were attributed to complement activation by structural features of the first-generation antagonist peptide backbone — specifically, the peptide's capacity to release histamine and activate the complement cascade, triggering systemic hypersensitivity responses. This safety signal led to restricted distribution and ultimately market withdrawal. The recognition of this liability directly motivated the development of degarelix, a second-generation GnRH antagonist with a modified peptide structure engineered to substantially reduce histamine-releasing activity, which is why degarelix has a dramatically lower rate of systemic allergic reactions despite sharing the same GnRH antagonist mechanism.
Option A: Option A is incorrect because abarelix was a competitive antagonist, not a partial agonist; it did not produce a testosterone flare and was studied specifically because of the anticipated flare-free advantage over agonists.
Option B: Option B is incorrect because permanent hypogonadism from pituitary gonadotroph toxicity is not an established adverse effect of abarelix or any GnRH antagonist; GnRH-mediated gonadotropin suppression is fully reversible upon drug discontinuation.
Option D: Option D is incorrect because QT interval prolongation with GnRH analogs is a consequence of testosterone suppression, a class effect shared by agonists and antagonists; abarelix does not have a direct peptide-related cardiac ion channel effect independent of hypogonadism.
Option E: Option E is incorrect because it conflates abarelix's clinical limitations with the dosing schedule of an entirely different drug class; abarelix did not require a separate daily induction regimen as its reason for withdrawal.
10. A 26-year-old man presents with absent puberty, undetectable LH and FSH, testosterone of 42 ng/dL, and anosmia. Evaluation confirms Kallmann syndrome with isolated GnRH deficiency. He desires fertility. Which of the following best describes the rationale and expected outcomes of pulsatile GnRH pump therapy for this patient?
A) Pulsatile GnRH therapy is contraindicated in Kallmann syndrome because anosmia indicates a structural olfactory bulb defect that prevents normal hypothalamic GnRH neuron migration, making the pituitary incapable of responding to exogenous pulsatile GnRH
B) Pulsatile GnRH therapy delivers continuous low-dose GnRH intravenously to stimulate sustained, tonic gonadotropin secretion; unlike depot agonists, it does not suppress the HPG axis because the dose is subthreshold for receptor downregulation
C) Pulsatile GnRH therapy using a portable pump is effective in restoring spermatogenesis in approximately 40% of men with Kallmann syndrome but is inferior to exogenous gonadotropin therapy for achieving pregnancies because gonadotropins bypass the pituitary
D) Pulsatile GnRH therapy is equivalent to high-dose testosterone replacement for restoring fertility in Kallmann syndrome because both normalize serum testosterone and provide the hormonal environment necessary for spermatogenesis
E) Pulsatile GnRH pump therapy delivers small doses of GnRH subcutaneously or intravenously every 60 to 120 minutes to mimic physiological hypothalamic pulsatile secretion, reliably inducing spermatogenesis in approximately 75 to 80% of men with hypogonadotropic hypogonadism and achieving cumulative pregnancy rates of 80 to 90% in women with the condition over multiple treatment cycles
ANSWER: E
Rationale:
Pulsatile GnRH pump therapy is the physiologically rational treatment for hypogonadotropic hypogonadism (HH) caused by isolated GnRH deficiency, including Kallmann syndrome. The pituitary gonadotrophs in these patients are structurally and functionally intact; the defect is in hypothalamic GnRH neuron migration and pulsatile GnRH delivery. A portable infusion pump delivers exogenous GnRH (2.5 to 20 mcg per pulse) subcutaneously or intravenously at intervals of 60 to 120 minutes, precisely mimicking physiological hypothalamic pulsatile secretion. Because the gonadotrophs receive appropriately pulsed GnRH stimulation, they respond by secreting LH and FSH in a physiological pattern, which in turn drives testicular Leydig cell testosterone production and Sertoli cell spermatogenesis. Spermatogenesis adequate for natural conception is achieved in approximately 75 to 80% of treated HH men, and cumulative pregnancy rates of 80 to 90% are reported in women with HH over multiple cycles. An important advantage over exogenous gonadotropin therapy in women is that pulsatile GnRH produces physiological, regulated gonadotropin levels, avoiding the supraphysiological FSH exposure and risk of multiple follicular development that complicate exogenous gonadotropin use.
Option A: Option A is incorrect because anosmia in Kallmann syndrome reflects failed olfactory neuron and GnRH neuron migration during fetal development, but the pituitary gonadotrophs themselves are fully functional and respond normally to exogenous pulsatile GnRH; anosmia does not indicate pituitary incapacity.
Option B: Option B is incorrect because the fundamental principle of pulsatile GnRH therapy is intermittent, not continuous delivery; continuous GnRH stimulation produces receptor downregulation and suppression (the mechanism of agonist depots), while pulsatile delivery maintains receptor responsiveness.
Option C: Option C is incorrect because spermatogenesis rates with pulsatile GnRH therapy in HH are approximately 75 to 80%, not 40%; the therapy is highly effective, not inferior to gonadotropin therapy for fertility outcomes.
Option D: Option D is incorrect because testosterone replacement does not restore fertility; exogenous testosterone suppresses pituitary LH and FSH secretion via negative feedback, shutting down spermatogenesis rather than restoring it.
11. A 34-year-old woman with moderate endometriosis-associated pain is being considered for elagolix therapy. Her gynecologist explains that elagolix offers a different pharmacodynamic profile compared with GnRH agonist depots. Which of the following best characterizes elagolix's pharmacokinetic properties and the clinical significance of its dose-dependent HPG axis suppression?
A) Elagolix has oral bioavailability of approximately 12% because it undergoes extensive first-pass intestinal peptidase hydrolysis; however, the fraction absorbed is sufficient to achieve sustained HPG axis suppression with once-daily dosing owing to high receptor binding affinity
B) Elagolix has oral bioavailability of approximately 57%, a plasma half-life of 4 to 6 hours, and produces dose-dependent HPG axis suppression: the 150 mg once-daily dose achieves partial estradiol suppression to early follicular phase levels, while the 200 mg twice-daily dose achieves near-complete suppression equivalent to surgical menopause, enabling clinically meaningful titration between pain control and adverse effects
C) Elagolix achieves sustained HPG axis suppression with once-daily dosing because of a long plasma half-life of approximately 25 hours that allows drug accumulation to steady-state plasma concentrations capable of maintaining complete GnRHR blockade throughout the dosing interval
D) Elagolix produces identical degrees of HPG axis suppression at both the 150 mg daily and 200 mg twice-daily doses; the clinical difference between doses is limited to tolerability, with the higher dose producing more vasomotor symptoms and bone mineral density loss without additional efficacy
E) Elagolix's non-peptide structure confers oral bioavailability, but its rapid metabolism by CYP3A4 limits the duration of GnRHR blockade to approximately 2 to 3 hours per dose, requiring three-times-daily administration to maintain continuous HPG axis suppression in clinical practice
ANSWER: B
Rationale:
Elagolix (Orilissa) is a non-peptide, small molecule GnRH receptor antagonist with oral bioavailability of approximately 57% — a consequence of its non-peptide structure, which resists intestinal peptidase hydrolysis that precludes oral activity for peptide-based GnRH analogs. Its plasma half-life of 4 to 6 hours and hepatic CYP3A4 metabolism support twice-daily dosing for the higher dose formulation. The most clinically important feature of elagolix's pharmacodynamics is dose-dependent HPG axis suppression: the 150 mg once-daily dose produces partial estradiol suppression to early follicular phase levels (approximately 12 to 73 pg/mL), reducing endometriosis pain while preserving partial ovarian function and minimizing bone mineral density (BMD) loss; the 200 mg twice-daily dose produces near-complete suppression (estradiol below 12 pg/mL, equivalent to surgical menopause), providing superior pain control at the cost of greater BMD loss and vasomotor symptoms. This titratable, dose-dependent partial-to-complete suppression is the key clinical differentiator of elagolix from GnRH agonist depots, which produce invariable, profound suppression at any approved dose.
Option A: Option A is incorrect because elagolix's oral bioavailability is approximately 57%, not approximately 12%; the ~12% bioavailability figure applies to relugolix. Elagolix's oral activity is not limited by intestinal peptidase hydrolysis — its non-peptide structure specifically avoids that problem.
Option C: Option C is incorrect because elagolix has a half-life of 4 to 6 hours, not approximately 25 hours; the 25-hour half-life applies to relugolix. Elagolix requires the 200 mg twice-daily dose to achieve near-complete suppression; once-daily dosing at that level is not supported.
Option D: Option D is incorrect because the two elagolix doses produce meaningfully different degrees of HPG suppression, not identical suppression; the dose-response relationship is a defining pharmacological characteristic of elagolix and the primary basis for selecting between doses.
Option E: Option E is incorrect because elagolix is approved for twice-daily dosing (200 mg twice daily) at the higher dose, not three-times-daily; the 4- to 6-hour half-life supports the approved dosing regimen.
12. A 31-year-old woman with HIV and moderate-to-severe endometriosis-associated pelvic pain is on antiretroviral therapy including ritonavir-boosted darunavir. Her gynecologist wants to start elagolix 200 mg twice daily. Which of the following best describes the pharmacokinetic interaction and appropriate clinical management?
A) Ritonavir inhibits P-glycoprotein transport of elagolix out of intestinal cells, increasing oral bioavailability by approximately 2-fold; the 200 mg twice-daily dose should be reduced to 150 mg twice daily to compensate
B) Ritonavir is a strong CYP2C8 inhibitor that increases elagolix exposure via the minor metabolic pathway; this interaction is clinically insignificant and no dose adjustment is required for the 200 mg twice-daily regimen
C) Ritonavir reduces elagolix exposure by inducing CYP3A4 at the net effect level despite also inhibiting CYP3A4 acutely; the result is subtherapeutic elagolix concentrations and inadequate endometriosis pain control, requiring a higher elagolix dose
D) Ritonavir is a strong CYP3A4 inhibitor that substantially increases elagolix plasma concentrations; the elagolix 200 mg twice-daily dose is contraindicated with strong CYP3A4 inhibitors because plasma levels reach potentially harmful concentrations, and alternative endometriosis management should be considered
E) The interaction between ritonavir and elagolix is bidirectional: elagolix inhibits CYP3A4, reducing ritonavir clearance and increasing ritonavir plasma levels, which may destabilize HIV viral suppression and requires antiretroviral dose adjustment
ANSWER: D
Rationale:
Elagolix undergoes extensive hepatic metabolism primarily via CYP3A4 (cytochrome P450 3A4), making it highly susceptible to interactions with strong CYP3A4 inhibitors. Ritonavir, a component of ritonavir-boosted darunavir, is one of the most potent CYP3A4 inhibitors in clinical use. When strong CYP3A4 inhibitors are co-administered with elagolix, elagolix plasma concentrations increase substantially. The elagolix 200 mg twice-daily dose is specifically contraindicated with strong CYP3A4 inhibitors (including ketoconazole, ritonavir, and clarithromycin) because at this dose the resulting plasma concentrations are potentially harmful. The prescribing information permits use of the 150 mg once-daily dose (which produces partial HPG suppression) with strong inhibitors in some circumstances, but the 200 mg twice-daily formulation is a hard contraindication. In this patient, starting elagolix 200 mg twice daily while on ritonavir-boosted antiretroviral therapy is contraindicated. Alternative endometriosis management strategies — including the lower elagolix dose with careful monitoring, or non-GnRH-based approaches — should be discussed.
Option A: Option A is incorrect because ritonavir is a CYP3A4 inhibitor, not primarily a P-glycoprotein inhibitor affecting elagolix bioavailability; the mechanism of interaction is CYP3A4-mediated reduction in elagolix metabolism, not P-gp transport inhibition. Additionally, reducing the dose to 150 mg twice daily is not a labeled dose for elagolix.
Option B: Option B is incorrect because ritonavir's primary interaction with elagolix is through CYP3A4 inhibition, not CYP2C8; while elagolix does have minor CYP2C8 metabolism, the major and clinically relevant pathway is CYP3A4.
Option C: Option C is incorrect because ritonavir is a potent net CYP3A4 inhibitor, not an inducer; at therapeutic doses ritonavir substantially inhibits CYP3A4, increasing elagolix exposure, not decreasing it.
Option E: Option E is incorrect because elagolix is a CYP3A4 substrate, not a significant CYP3A4 inhibitor; it does not meaningfully inhibit ritonavir clearance, and the concern here is elagolix toxicity from impaired metabolism, not antiretroviral destabilization.
13. A 71-year-old man with advanced prostate cancer is on relugolix 120 mg once daily for androgen deprivation therapy. He is admitted with new-onset atrial fibrillation and started on amiodarone. Which of the following best describes the pharmacokinetic interaction and its clinical significance?
A) Amiodarone is a strong inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), the primary transport proteins governing relugolix absorption and elimination; co-administration can increase relugolix exposure up to 4-fold, raising the risk of prolonged testosterone suppression and adverse effects, making this combination contraindicated or requiring relugolix dose reduction
B) Amiodarone inhibits CYP3A4, reducing relugolix clearance and increasing plasma concentrations; the interaction is moderate in magnitude and can be managed by reducing the relugolix dose by 50% with close testosterone monitoring
C) Amiodarone induces P-glycoprotein at steady state, reducing intestinal absorption of relugolix and potentially resulting in loss of testosterone suppression; the relugolix dose should be doubled to compensate for the reduced bioavailability
D) Relugolix is a major CYP3A4 substrate, and amiodarone's inhibition of CYP3A4 substantially increases relugolix plasma concentrations; the interaction risk is equivalent to that seen with ketoconazole and is managed the same way as for elagolix co-administered with strong CYP3A4 inhibitors
E) Amiodarone and relugolix do not interact pharmacokinetically; the clinical concern in this patient is additive QT prolongation from relugolix-related testosterone suppression combined with amiodarone's direct cardiac ion channel effects, requiring baseline and repeat ECG monitoring
ANSWER: A
Rationale:
Relugolix is a substrate and moderate inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Its drug interaction profile is fundamentally different from elagolix, which is primarily a CYP3A4 substrate: relugolix is not significantly metabolized by CYP3A4, and P-gp/BCRP-mediated transport governs its absorption and disposition. Amiodarone is a well-established strong P-gp inhibitor. When amiodarone is co-administered with relugolix, P-gp-mediated efflux of relugolix from intestinal enterocytes is reduced, increasing intestinal absorption and systemic exposure. Clinical data indicate that strong P-gp inhibitors can increase relugolix exposure up to 4-fold. This substantially raises the risk of adverse effects associated with prolonged deep testosterone suppression, and the combination is contraindicated in the prescribing information or requires relugolix dose reduction depending on clinical circumstances. Other strong P-gp inhibitors presenting similar risk include clarithromycin, itraconazole, and verapamil.
Option B: Option B is incorrect because the relugolix-amiodarone interaction is mediated by P-gp inhibition, not CYP3A4; amiodarone does inhibit CYP3A4, but relugolix is not a major CYP3A4 substrate, so the CYP3A4 pathway is not the clinically relevant mechanism here.
Option C: Option C is incorrect because amiodarone is a P-gp inhibitor, not an inducer; it increases relugolix exposure rather than reducing it. P-gp inducers (rifampin, carbamazepine) would reduce relugolix exposure.
Option D: Option D is incorrect because the relugolix-amiodarone interaction is P-gp mediated, not CYP3A4 mediated; this is a key differentiator between relugolix and elagolix drug interaction profiles. Relugolix's interaction management is not equivalent to the elagolix-ketoconazole CYP3A4 interaction.
Option E: Option E is incorrect because there is a significant pharmacokinetic interaction between amiodarone and relugolix via P-gp inhibition; stating that no pharmacokinetic interaction exists would be clinically incorrect and could lead to inadequate dose management.
14. A 74-year-old man with metastatic hormone-sensitive prostate cancer has a history of myocardial infarction 4 months ago and current ejection fraction of 38%. His oncologist is selecting between leuprolide depot and relugolix for androgen deprivation therapy. Which of the following best summarizes the key findings of the HERO trial that are most relevant to this patient's clinical situation?
A) The HERO trial demonstrated that relugolix and leuprolide produced equivalent rates of castrate testosterone suppression at 48 weeks (approximately 88% for both agents), but relugolix had a statistically significant improvement in progression-free survival, establishing it as the preferred agent for all metastatic prostate cancer patients regardless of cardiovascular history
B) The HERO trial was a phase 2 dose-finding study that established the 120 mg once-daily dose of relugolix as the minimum effective dose for testosterone suppression; the cardiovascular comparison with leuprolide was a secondary exploratory endpoint without sufficient statistical power to guide clinical decision-making
C) In the HERO trial, relugolix 120 mg once daily achieved sustained castrate testosterone levels in 96.7% of patients at 48 weeks compared with 88.8% for leuprolide; the relugolix arm had a 54% lower rate of major adverse cardiovascular events (MACE), and testosterone recovered more rapidly after relugolix discontinuation (mean 288 ng/dL vs. 58 ng/dL at 90 days), making relugolix the preferred choice in patients with established cardiovascular disease
D) The HERO trial showed that relugolix produced a testosterone flare in approximately 12% of patients during the loading dose phase, similar in magnitude to that seen with leuprolide depot; the cardiovascular benefit was attributable to anti-inflammatory properties of the drug rather than to differences in testosterone suppression kinetics
E) The HERO trial demonstrated that relugolix was inferior to leuprolide in achieving castrate testosterone at 48 weeks but superior in time to testosterone suppression onset; the cardiovascular benefit was driven entirely by the absence of testosterone flare at initiation rather than by any difference in long-term testosterone levels
ANSWER: C
Rationale:
The HERO (Hormonal Treatment with Relugolix in Men with Prostate Cancer) phase 3 trial enrolled men with advanced prostate cancer and randomized them to relugolix 120 mg once daily (after a 360 mg loading dose) versus injectable leuprolide. Relugolix achieved sustained castrate testosterone levels (below 50 ng/dL) in 96.7% of patients at 48 weeks, compared with 88.8% for leuprolide — a statistically significant difference favoring relugolix. Critically for this patient with recent MI and reduced ejection fraction, the relugolix arm had a 54% lower rate of major adverse cardiovascular events (MACE) compared with leuprolide. This cardiovascular advantage is attributed to two mechanisms: relugolix's short half-life (approximately 25 hours) allows testosterone to recover more rapidly after treatment completion (mean 288 ng/dL in the relugolix group versus 58 ng/dL in the leuprolide group at 90 days post-discontinuation), and relugolix avoids the sustained testosterone suppression-related metabolic effects inherent to long-acting depot agonists. For a patient with MI within 6 months and heart failure, relugolix is the strongly preferred choice over leuprolide.
Option A: Option A is incorrect because the HERO trial did not show equivalent castration rates; relugolix (96.7%) was superior to leuprolide (88.8%). The trial was not powered or designed as a progression-free survival study; the MACE finding was a prespecified secondary endpoint.
Option B: Option B is incorrect because HERO was a phase 3 randomized controlled trial, not a dose-finding phase 2 study; the cardiovascular comparison was a prespecified secondary endpoint with adequate statistical rigor to support clinical guideline recommendations.
Option D: Option D is incorrect because relugolix produced no testosterone flare at initiation — the absence of flare is a defining advantage of the antagonist class and was confirmed in the HERO trial. The cardiovascular benefit was related to faster testosterone recovery and avoidance of metabolic effects, not to anti-inflammatory drug properties.
Option E: Option E is incorrect because relugolix was not inferior to leuprolide in castration rates at 48 weeks — it was superior; the cardiovascular benefit reflects both faster testosterone recovery and avoidance of sustained metabolic sequelae, not solely the absence of the initial flare.
15. A 29-year-old woman with confirmed endometriosis is started on elagolix 150 mg once daily. Her gynecologist explains that this dose was chosen specifically because it achieves a different degree of estrogen suppression compared with both the higher elagolix dose and GnRH agonist depot therapy. Which of the following best characterizes the pharmacodynamic profile of elagolix 150 mg once daily?
A) Elagolix 150 mg once daily achieves near-complete HPG axis suppression equivalent to surgical menopause, suppressing estradiol to below 12 pg/mL in most patients; it is preferred over the 200 mg twice-daily dose primarily because of lower cost and simpler once-daily dosing
B) Elagolix 150 mg once daily achieves complete GnRHR occupancy but produces only partial estradiol suppression because the receptor affinity at this dose is insufficient to block the FSH-driven follicular estradiol synthesis that occurs in the late follicular phase
C) Elagolix 150 mg once daily and GnRH agonist depots produce identical degrees of estradiol suppression over the treatment period; the clinical advantage of elagolix is its oral route and reversibility, not any pharmacodynamic difference in depth of HPG suppression
D) Elagolix 150 mg once daily suppresses estradiol to below 10 pg/mL within the first 2 weeks of therapy, achieving castration-equivalent suppression that makes add-back therapy mandatory from the first day of treatment to prevent bone mineral density loss
E) Elagolix 150 mg once daily produces partial HPG axis suppression, maintaining estradiol at approximately early follicular phase levels (approximately 12 to 73 pg/mL), which reduces endometriosis pain while preserving partial ovarian function and substantially attenuating the bone mineral density loss and vasomotor symptoms associated with near-complete suppression
ANSWER: E
Rationale:
Elagolix's dose-dependent pharmacodynamic profile is its defining clinical characteristic. The 150 mg once-daily dose achieves partial HPG axis suppression, maintaining estradiol at approximately early follicular phase levels — roughly 12 to 73 pg/mL. This partial suppression is clinically meaningful: it is sufficient to reduce estrogen-dependent endometriosis pain (dysmenorrhea and non-menstrual pelvic pain) in the majority of patients while preserving partial ovarian function. Critically, because estradiol does not fall to castrate levels, bone mineral density (BMD) loss is substantially attenuated compared with near-complete suppression, and vasomotor symptoms are less severe. This creates a pharmacodynamic window not achievable with GnRH agonist depot therapy, which invariably drives estradiol to castrate levels regardless of dose. At the 150 mg once-daily dose, elagolix is approved for up to 24 months of use without mandatory add-back therapy (with appropriate BMD monitoring).
Option A: Option A is incorrect because near-complete HPG suppression equivalent to surgical menopause (estradiol below 12 pg/mL) is the pharmacodynamic profile of elagolix 200 mg twice daily, not 150 mg once daily; the two doses have clinically meaningful differences in depth of suppression, and this distinction is the primary basis for dose selection.
Option B: Option B is incorrect because elagolix 150 mg once daily produces partial suppression through dose-dependent partial GnRHR occupancy/antagonism, not through insufficient receptor affinity; the mechanism is competitive antagonism where lower doses achieve less complete receptor blockade.
Option C: Option C is incorrect because GnRH agonist depots produce profound, non-titratable estradiol suppression to castrate levels, not partial suppression equivalent to the elagolix 150 mg dose; the pharmacodynamic difference between elagolix at the lower dose and depot agonists is substantial, not trivial.
Option D: Option D is incorrect because elagolix 150 mg once daily does not achieve castration-equivalent estradiol suppression; the partial suppression at this dose does not reach below 10 pg/mL in most patients, and mandatory add-back therapy from day one is not required — it is the ability to use this dose without mandatory add-back for up to 24 months that distinguishes the 150 mg dose from the 200 mg twice-daily regimen.
16. A 37-year-old woman with stage III endometriosis has been on leuprolide depot 3.75 mg monthly for 3 months and has excellent pain control but reports severe hot flashes and has lost 3% lumbar spine bone mineral density on repeat DEXA. Her gynecologist plans to add add-back therapy. Which of the following best describes the physiological rationale for the estrogen threshold principle that guides add-back therapy dosing?
A) Add-back therapy with high-dose estrogen (estradiol above 60 pg/mL) is required to prevent bone mineral density loss because bone protection requires supraphysiological estrogen levels; endometriosis lesions do not respond to estrogen above 50 pg/mL owing to receptor downregulation from prior estrogen deprivation
B) The estrogen threshold principle holds that endometriosis implants require estradiol above approximately 20 pg/mL to grow and produce symptoms, while bone protection requires estradiol above approximately 30 to 40 pg/mL; add-back therapy targets the 20 to 40 pg/mL window, which is below the threshold for endometriosis stimulation but sufficient for bone protection
C) The estrogen threshold principle refers to the minimum estrogen level required to suppress FSH below the threshold for follicular recruitment; add-back therapy prevents iatrogenic premature ovarian insufficiency by maintaining estradiol above 50 pg/mL throughout GnRH agonist treatment
D) Add-back therapy with norethindrone acetate alone is insufficient for bone protection because progestins do not influence bone mineral density; combined estrogen plus progestin is required in all patients receiving GnRH agonist therapy for more than 3 months
E) The estrogen threshold principle was established in clinical trials showing that estradiol below 10 pg/mL was necessary for complete endometriosis symptom control; add-back therapy is therefore contraindicated in patients who have residual pain on GnRH agonist therapy because it risks reactivating endometriosis implants
ANSWER: B
Rationale:
The estrogen threshold principle is the pharmacological foundation for add-back therapy during GnRH agonist or antagonist treatment for endometriosis. Endometriosis implants require estradiol above approximately 20 pg/mL to grow, bleed, and generate the inflammatory mediators responsible for pain. Bone mineral density loss from hypoestrogenism occurs when estradiol falls below approximately 30 to 40 pg/mL. These two thresholds create a therapeutic window: maintaining estradiol in the 20 to 40 pg/mL range is low enough to suppress endometriosis activity while being sufficient for bone protection. Add-back therapy — typically norethindrone acetate 5 mg daily alone, or conjugated equine estrogen 0.625 mg plus norethindrone acetate 5 mg, or the combined formulation norethindrone acetate 1 mg used as add-back with elagolix 200 mg twice daily — is designed to place estradiol within this window. Importantly, clinical trials have confirmed that appropriately dosed add-back therapy does not significantly reduce the pain control efficacy of GnRH agonist therapy.
Option A: Option A is incorrect because estradiol levels above 60 pg/mL would exceed the threshold for endometriosis stimulation (approximately 20 pg/mL) and would likely reactivate implants; the add-back target is specifically the 20 to 40 pg/mL range, not supraphysiological levels.
Option C: Option C is incorrect because the estrogen threshold principle is not about FSH suppression or preventing premature ovarian insufficiency; it describes the differential sensitivity of endometriosis implants versus bone to estradiol levels. Maintaining estradiol above 50 pg/mL would risk reactivating endometriosis.
Option D: Option D is incorrect because norethindrone acetate alone does provide meaningful bone protection through progestin-mediated effects on bone metabolism; norethindrone acetate 5 mg daily without estrogen is an approved add-back option for women who cannot take estrogen.
Option E: Option E is incorrect because the estrogen threshold for endometriosis stimulation is approximately 20 pg/mL, not below 10 pg/mL; add-back therapy targeting 20 to 40 pg/mL is specifically designed to be compatible with ongoing endometriosis pain control, and it is not contraindicated in patients with residual pain.
17. A 7-year-old girl presents with breast development, pubic hair, and a bone age 2 years advanced beyond chronological age. Pelvic ultrasound shows ovarian follicular development consistent with gonadotropin stimulation. GnRH stimulation testing confirms central precocious puberty (CPP). Which of the following best describes the standard pharmacological management and the criterion used to confirm adequacy of HPG axis suppression?
A) Histrelin subcutaneous implant is the only approved treatment for central precocious puberty in girls because leuprolide depot failed to show consistent LH suppression in randomized trials in prepubertal females; implant replacement is required every 6 months
B) Treatment with a GnRH antagonist such as degarelix is preferred over GnRH agonist depot in central precocious puberty because antagonists achieve suppression without any initial LH surge, preventing the brief worsening of puberty that occurs in the first 2 weeks of agonist therapy
C) Leuprolide depot for central precocious puberty should be dosed at 1.0 mg/kg intramuscularly every 4 weeks; adequacy of suppression is confirmed by a peak stimulated LH below 10 IU/L on GnRH stimulation testing at 3 months
D) Leuprolide depot (Lupron Depot-Ped) at 0.3 mg/kg (minimum 7.5 mg) intramuscularly every 4 weeks is the standard initial regimen for central precocious puberty; adequacy of HPG axis suppression is confirmed by a stimulated LH peak below 2 IU/L (IU per liter) after GnRH or GnRH agonist stimulation at 30 to 60 minutes
E) GnRH agonist therapy for central precocious puberty is initiated only after the bone age exceeds 10 years in girls and 11 years in boys, because treatment before these ages is not effective at preserving final adult height owing to insufficient skeletal growth remaining at epiphyseal plates
ANSWER: D
Rationale:
Central precocious puberty (CPP), defined as HPG axis activation before age 8 in girls and age 9 in boys, is treated with GnRH agonist depot therapy to halt pubertal progression and protect final adult height by extending the period of skeletal growth before epiphyseal fusion. The standard initial regimen is leuprolide depot (Lupron Depot-Pediatric) at 0.3 mg/kg (with a minimum dose of 7.5 mg) given intramuscularly every 4 weeks. This creates continuous, non-pulsatile GnRHR occupancy that desensitizes pituitary gonadotrophs and suppresses LH and FSH secretion. Adequacy of HPG axis suppression is confirmed by demonstrating that a stimulated LH peak is below 2 IU/L (IU per liter) after GnRH or GnRH agonist stimulation at 30 to 60 minutes — this confirms that the pituitary gonadotroph has been effectively downregulated. A 3-month formulation of leuprolide (11.25 mg and 30 mg) and annual histrelin subcutaneous implants are also approved for CPP, offering alternatives to monthly dosing.
Option A: Option A is incorrect because leuprolide depot is an approved and extensively used first-line treatment for CPP; histrelin implant is an effective alternative but is not the only approved agent, and it requires annual rather than every-6-months replacement.
Option B: Option B is incorrect because GnRH antagonists such as degarelix are not approved for and have not replaced GnRH agonist depots as the standard of care in CPP; while the initial LH surge with agonist therapy is theoretically a concern, it is clinically transient and generally not clinically significant in this indication.
Option C: Option C is incorrect because the standard leuprolide dose for CPP is 0.3 mg/kg, not 1.0 mg/kg; 1.0 mg/kg would represent a substantial overdose. The LH suppression target is below 2 IU/L on stimulated testing, not below 10 IU/L.
Option E: Option E is incorrect because GnRH agonist therapy for CPP is initiated at the time of diagnosis to halt premature puberty, not deferred until a specific bone age threshold; the goal of treatment is precisely to prevent further bone age advancement and protect final adult height, so early intervention when bone age is already advanced is the appropriate approach.
18. A 77-year-old man with metastatic prostate cancer is about to begin leuprolide depot. His medication list includes methadone 80 mg daily for chronic pain and fluconazole for a recent fungal infection. His baseline QTc is 468 ms. Which of the following best describes the cardiovascular risk and recommended management in this patient?
A) GnRH agonist therapy prolongs QTc by approximately 10 to 20 milliseconds through testosterone suppression-induced prolongation of the cardiac action potential; concurrent use of methadone and fluconazole — both established QT-prolonging agents — creates a high-risk combination that warrants a baseline ECG and repeat ECG at 1 to 3 months, and this patient's baseline QTc of 468 ms is an additional risk factor requiring cardiology input before initiation
B) The QT prolongation risk with GnRH agonists is a direct drug effect of the leuprolide peptide on cardiac ion channels, independent of testosterone suppression; switching to degarelix eliminates this risk because antagonists do not affect cardiac ion channels
C) Methadone and fluconazole are safe to continue unchanged because the QT-prolonging effect of GnRH agonist therapy is self-limiting, returning to baseline once testosterone reaches castrate levels at 3 to 4 weeks; the initial flare phase carries the only meaningful QT prolongation risk
D) A baseline QTc of 468 ms is below the threshold of clinical concern for GnRH agonist therapy; cardiac monitoring is only required when baseline QTc exceeds 500 ms, and no additional ECG surveillance is needed in this patient as long as current QT-prolonging medications are continued at their current doses
E) Fluconazole poses no QT interaction risk with GnRH agonist therapy because it is metabolized by CYP3A4 and does not directly inhibit cardiac potassium channels; methadone is the only agent requiring dose adjustment before leuprolide initiation
ANSWER: A
Rationale:
Androgen deprivation therapy (ADT)-induced testosterone suppression prolongs the cardiac action potential duration and increases the corrected QT interval (QTc); pooled clinical data suggest GnRH agonist therapy increases QTc by approximately 10 to 20 milliseconds on average. This baseline increase, added to the QT-prolonging effects of concurrent medications, creates a clinically meaningful cumulative risk. This patient has three converging QT risk factors: leuprolide-induced testosterone suppression, methadone (a well-established QT-prolonging opioid with direct hERG potassium channel blockade), and fluconazole (an azole antifungal that prolongs QT through hERG channel inhibition and also inhibits CYP3A4-mediated methadone metabolism, further increasing methadone exposure). A baseline QTc of 468 ms already reflects some prolongation above the upper limit of normal (approximately 440 ms in men), and this patient would benefit from cardiology consultation before ADT initiation. A baseline ECG is prudent, and repeat ECG at 1 to 3 months after starting ADT is recommended when concurrent QT-prolonging drugs are present. Patients with congenital long QT syndrome or QTc above 500 ms at baseline should not receive GnRH agonists without cardiology input.
Option B: Option B is incorrect because the QT-prolonging effect of GnRH analogs is mediated by testosterone suppression, not by a direct drug effect on cardiac ion channels; this is a class effect shared by all GnRH agonists and antagonists, including degarelix and relugolix, which suppress testosterone equally. Switching to degarelix does not eliminate QT risk.
Option C: Option C is incorrect because the QT-prolonging effect of ADT is ongoing and persists throughout treatment; it does not resolve once castrate testosterone levels are reached — sustained hypogonadism maintains QTc prolongation for the duration of ADT. The concern is continuous, not limited to the flare phase.
Option D: Option D is incorrect because a baseline QTc of 468 ms in the setting of multiple QT-prolonging co-medications is a clinically relevant risk factor warranting monitoring; the 500 ms threshold mentioned is a stricter criterion for considering GnRH agonist avoidance, not the only level requiring attention.
Option E: Option E is incorrect because fluconazole does prolong QT through hERG channel inhibition; this is well-established and is the basis for fluconazole warnings against co-administration with other QT-prolonging drugs.
19. A 68-year-old man with high-risk prostate cancer has been on continuous leuprolide depot for 18 months. His baseline DEXA showed a lumbar spine T-score of -1.4. He is on calcium 1,000 mg daily and vitamin D 1,000 IU daily. Repeat DEXA shows a lumbar spine T-score of -2.1. He has no prior fracture history. Which of the following best describes the appropriate bone protection strategy and monitoring plan?
A) No additional pharmacological bone protection is indicated because calcium and vitamin D supplementation are sufficient to prevent clinically significant bone loss in all men on ADT, and the T-score change from -1.4 to -2.1 is within the expected range of measurement variability for DEXA
B) Testosterone replacement should be initiated at a low dose to partially restore bone protection while maintaining prostate cancer control, because the bone protective effects of testosterone supplementation outweigh the risk of disease progression when PSA remains undetectable
C) Bisphosphonate therapy with zoledronic acid 4 mg intravenously every 12 months or denosumab 60 mg subcutaneously every 6 months should be initiated; men on ADT with a T-score below -1.0 at baseline, ongoing testosterone suppression, or high fracture risk meet criteria for bone-protective pharmacotherapy beyond calcium and vitamin D supplementation alone
D) The T-score decline from -1.4 to -2.1 is an expected consequence of ADT but does not require pharmacological intervention until the patient sustains an actual fragility fracture, because prophylactic bisphosphonate therapy in the absence of a clinical fracture has not been shown to improve quality-adjusted outcomes in prostate cancer patients
E) ADT-related bone loss is completely reversible upon testosterone recovery after ADT discontinuation; no pharmacological bone protection is required during active treatment because DEXA normalization after treatment cessation eliminates long-term fracture risk
ANSWER: C
Rationale:
Bone mineral density (BMD) loss is the most clinically significant long-term adverse effect of GnRH-mediated testosterone suppression in men, with BMD declining by approximately 2 to 3% per year at the lumbar spine and femoral neck. Fracture risk increases significantly after 12 months of ADT. This patient has multiple risk factors for pharmacological bone protection: a baseline T-score of -1.4 (already in the osteopenic range, below -1.0), progression to -2.1 (approaching osteoporosis threshold of -2.5) despite calcium and vitamin D supplementation, and ongoing continuous ADT. Per established guidelines, indications for bone-protective pharmacotherapy beyond calcium and vitamin D include T-score below -1.0 at baseline, history of fragility fracture, or ADT duration exceeding 12 months in high-risk patients. Zoledronic acid 4 mg IV every 12 months and denosumab 60 mg SC every 6 months are both standard-of-care bone-protective agents in this setting, with denosumab having the strongest evidence base in ADT-related bone loss.
Option A: Option A is incorrect because calcium and vitamin D alone are not sufficient to prevent clinically significant bone loss at the rates seen in men on continuous ADT; this patient's documented T-score decline to -2.1 despite supplementation demonstrates the inadequacy of supplementation alone.
Option B: Option B is incorrect because testosterone replacement in a man with prostate cancer on ADT is contraindicated; testosterone drives prostate cancer growth and the bone loss is an accepted adverse effect requiring non-hormonal bone protection, not testosterone supplementation.
Option D: Option D is incorrect because the standard of care for ADT-related bone loss is prophylactic bone-protective therapy in high-risk patients, not waiting for a clinical fracture; fragility fractures in elderly men are associated with high morbidity and mortality, and waiting for a fracture before intervening is not the accepted approach.
Option E: Option E is incorrect because ADT-related bone loss is not fully reversible; while some BMD recovery occurs after testosterone normalizes following ADT discontinuation, recovery is incomplete, especially after prolonged suppression, and fracture risk may remain elevated. Waiting for natural recovery is not the appropriate management strategy.
20. A 65-year-old man has been on leuprolide depot for 12 months for locally advanced prostate cancer. At his follow-up visit he reports weight gain of 8 kg, mostly abdominal, decreased muscle mass, and fatigue. His fasting glucose is 118 mg/dL (up from 92 mg/dL at baseline) and his HDL (high-density lipoprotein) cholesterol has fallen from 48 to 34 mg/dL with a rise in triglycerides from 130 to 228 mg/dL. Which of the following best explains the mechanism and expected metabolic trajectory of these findings?
A) These findings represent a direct hepatotoxic effect of leuprolide acetate that impairs hepatic lipid metabolism and gluconeogenesis regulation; switching to degarelix will reverse the lipid abnormalities because degarelix uses a different peptide backbone that does not accumulate in hepatocytes
B) The metabolic changes are caused by leuprolide-induced suppression of FSH, which normally stimulates adipose tissue lipolysis; the dyslipidemia and insulin resistance will resolve within 4 weeks of adding an FSH-replacement supplement to the ADT regimen
C) These findings represent a drug-specific adverse effect of leuprolide's PLGA polymer carrier, not of testosterone suppression; switching to goserelin or triptorelin, which use different polymer matrices, will prevent further metabolic deterioration
D) The metabolic changes reflect leuprolide-induced elevation of serum estradiol as a consequence of peripheral testosterone aromatization during the initial testosterone flare phase; they will resolve once castrate testosterone levels eliminate the aromatization substrate
E) These findings are consistent with the metabolic syndrome of sustained hypogonadism from ADT, comprising visceral adiposity, decreased lean muscle mass, insulin resistance, and dyslipidemia; this constellation increases the risk of type 2 diabetes by approximately 40% and cardiovascular events by 10 to 20% over 1 to 5 years, and is managed with lifestyle intervention and guideline-directed cardiovascular and metabolic screening
ANSWER: E
Rationale:
The metabolic changes in this patient — visceral weight gain, decreased muscle mass, rising fasting glucose, falling HDL cholesterol, and rising triglycerides — are the classic components of ADT-induced metabolic syndrome, a well-characterized consequence of sustained hypogonadism in men. Testosterone has anabolic effects on skeletal muscle and anti-adipogenic effects on adipose tissue; its suppression promotes increases in visceral adiposity and decreases in lean muscle mass. Insulin resistance develops through multiple mechanisms including increased visceral fat mass, reduced skeletal muscle glucose uptake, and direct effects of hypogonadism on insulin signaling. Dyslipidemia (elevated triglycerides, reduced HDL) is a direct consequence of the metabolic syndrome and testosterone deficiency. These changes increase the risk of type 2 diabetes by approximately 40% and major cardiovascular events by 10 to 20% over 1 to 5 years of ADT. This is a class effect of all GnRH-mediated testosterone suppression, regardless of the specific agonist or antagonist used. Management includes regular aerobic and resistance exercise (which meaningfully attenuates ADT-induced metabolic changes), dietary modification, baseline and follow-up screening for diabetes and cardiovascular risk factors every 3 to 6 months, and statin therapy per cardiovascular risk guidelines.
Option A: Option A is incorrect because ADT-induced metabolic syndrome is caused by testosterone suppression, not by hepatotoxicity of the leuprolide peptide or its carrier; switching to degarelix does not reverse these metabolic changes because the mechanism is shared by all agents that suppress testosterone to castrate levels.
Option B: Option B is incorrect because the metabolic changes are caused by testosterone suppression, not by FSH suppression; no FSH-replacement supplement exists or is indicated in this context.
Option C: Option C is incorrect because the metabolic changes are a consequence of testosterone suppression and are not related to the specific polymer delivery system (PLGA, atrigel, or goserelin's glycolide-lactide copolymer); switching polymer systems does not alter the metabolic outcome.
Option D: Option D is incorrect because these metabolic changes are not caused by estradiol elevation during the flare phase; they develop progressively as a consequence of sustained hypogonadism, not acutely from the initial testosterone surge, and they persist throughout the duration of ADT.
21. A 63-year-old man had radical prostatectomy for prostate cancer 3 years ago and now has a rising PSA at 1.8 ng/mL with no evidence of metastases on imaging. He is started on leuprolide depot, achieves a PSA nadir of less than 0.2 ng/mL at 8 months, and his testosterone is suppressed to 18 ng/dL. His oncologist discusses intermittent versus continuous ADT. Which of the following best describes the evidence base and clinical rationale for intermittent ADT in this patient?
A) Intermittent ADT is contraindicated in patients with biochemically recurrent prostate cancer because PSA elevation during treatment holidays indicates disease progression and each off-cycle period promotes the selection of castration-resistant clones, resulting in significantly worse overall survival compared with continuous ADT
B) Intermittent ADT, in which treatment cycles are guided by PSA thresholds with treatment holidays when PSA is suppressed, has been shown to provide comparable overall survival to continuous ADT in men with biochemically recurrent non-metastatic prostate cancer, while allowing partial testosterone recovery during off-treatment periods that may mitigate some long-term adverse effects including metabolic syndrome and quality-of-life impairments
C) Intermittent ADT is a validated approach for metastatic hormone-sensitive prostate cancer that improves overall survival compared with continuous ADT because the testosterone recovery during off-cycles resensitizes the tumor to subsequent androgen suppression, a principle known as androgen cycling therapy
D) Intermittent ADT is only appropriate when using oral GnRH antagonists such as relugolix, because the short half-life of oral antagonists allows rapid testosterone recovery during off-cycles; depot agonists cannot be used for intermittent ADT because testosterone recovery after a 3-month depot requires 6 to 9 months, eliminating any practical off-cycle benefit
E) Intermittent ADT should be initiated from the start of treatment rather than after achieving a PSA nadir, because starting treatment holidays before full testosterone suppression is achieved preserves Leydig cell function and leads to faster testosterone recovery in subsequent off-cycles
ANSWER: B
Rationale:
Intermittent ADT is a clinically validated strategy for biochemically recurrent prostate cancer without radiographic metastases. In this approach, androgen deprivation is initiated and continued until a PSA nadir is achieved (typically below 0.2 to 4 ng/mL depending on protocol), at which point therapy is suspended; treatment is restarted when PSA rises above a predefined threshold (commonly 10 to 20 ng/mL in non-metastatic disease). Multiple randomized trials comparing intermittent with continuous ADT in men with biochemically recurrent non-metastatic prostate cancer have demonstrated comparable overall survival between the two approaches in this setting. The clinical benefit of intermittent ADT is the partial testosterone recovery during off-treatment periods, which attenuates some of the long-term adverse effects of sustained hypogonadism — including metabolic syndrome, bone loss, and quality-of-life impairments such as fatigue, sexual dysfunction, and hot flashes. This patient — with PSA-only recurrence after prostatectomy and no metastatic disease — is an appropriate candidate for intermittent ADT discussion.
Option A: Option A is incorrect because intermittent ADT does not significantly worsen overall survival compared with continuous ADT in biochemically recurrent non-metastatic disease; multiple randomized controlled trials have demonstrated comparable survival, and guideline bodies support intermittent ADT as an option in this setting.
Option C: Option C is incorrect because the evidence for comparable overall survival with intermittent ADT applies specifically to biochemically recurrent non-metastatic disease, not to metastatic hormone-sensitive prostate cancer, where continuous ADT is the standard; the concept of androgen cycling therapy does not have prospective evidence supporting improved survival in metastatic disease.
Option D: Option D is incorrect because intermittent ADT can be implemented with either depot agonists or oral antagonists; depot agonists have been used in the majority of intermittent ADT trials, and while testosterone recovery is slower after a 3-month depot, off-cycle intervals of 6 to 12 months or longer are still clinically feasible and beneficial.
Option E: Option E is incorrect because intermittent ADT protocols initiate treatment holidays after achieving a confirmed PSA nadir and period of sustained suppression, not from the outset of treatment; beginning cycles before adequate testosterone suppression provides neither the oncological benefit of ADT nor meaningful off-cycle recovery.
22. A 70-year-old man with metastatic hormone-sensitive prostate cancer is starting continuous ADT with leuprolide 22.5 mg IM depot every 3 months. He has no baseline cardiovascular disease and a baseline DEXA T-score of -0.8. Which of the following best describes the complete standard monitoring program during ongoing ADT?
A) The only monitoring required during ADT is PSA every 6 months to assess treatment response; testosterone levels are not useful because all patients achieve castrate levels with depot therapy, and metabolic and bone monitoring are only indicated if clinical symptoms develop
B) Monitoring during ADT should include PSA every 3 months, serum testosterone weekly for the first 3 months to detect non-castrate levels, followed by annual DEXA; no routine metabolic screening is required unless the patient has a preexisting diagnosis of diabetes or dyslipidemia
C) ADT monitoring requires annual PSA, annual testosterone, and a one-time DEXA at 5 years of treatment; more frequent laboratory monitoring has not been shown to improve outcomes and increases healthcare costs without benefit in men with suppressed PSA
D) Standard ADT monitoring in prostate cancer includes PSA every 3 to 6 months, serum testosterone before each depot injection or every 3 to 6 months for oral agents to confirm castrate levels, a fasting metabolic panel (glucose, lipids, HbA1c) every 3 to 6 months, and DEXA at baseline with repeat at 12 months for men on continuous ADT; depression and sexual dysfunction should also be assessed at each visit
E) The monitoring schedule for ADT should be identical to that for non-ADT prostate cancer surveillance, consisting of PSA every 6 months and annual physical examination; additional laboratory monitoring for metabolic or cardiac changes is the responsibility of the patient's primary care physician rather than the oncology team managing ADT
ANSWER: D
Rationale:
Monitoring during ADT for prostate cancer is multidimensional and guided by the multiple organ systems affected by sustained testosterone suppression. PSA every 3 to 6 months detects treatment response and early biochemical progression. Serum testosterone should be measured before each depot injection (or every 3 to 6 months for oral agents once steady-state suppression is established) to confirm castrate levels (below 50 ng/dL by traditional criteria, below 20 ng/dL by newer guidelines) and to detect non-castrate testosterone that may signal delivery failure or end-of-dose escape. A fasting metabolic panel — including fasting glucose, lipids, and hemoglobin A1c (HbA1c) — is recommended every 3 to 6 months because of the substantial risk of developing insulin resistance, type 2 diabetes, and dyslipidemia during ADT. Baseline DEXA scanning is recommended before ADT initiation, with repeat DEXA at 12 months in men on continuous ADT; for patients with T-scores indicating osteopenia or osteoporosis, or those on prolonged ADT, pharmacological bone protection is indicated. Depression and sexual dysfunction are common, often underreported adverse effects of hypogonadism and should be proactively assessed.
Option A: Option A is incorrect because testosterone monitoring before depot injections is essential practice in ADT management; non-castrate testosterone occurs in approximately 4 to 13% of patients and is clinically actionable. Restricting monitoring to PSA alone misses the metabolic and bone adverse effects that affect morbidity and quality of life.
Option B: Option B is incorrect because weekly testosterone monitoring is not standard practice; testosterone should be checked at each injection visit. Metabolic panel screening is recommended for all ADT patients, not only those with preexisting conditions.
Option C: Option C is incorrect because annual PSA and one-time DEXA at 5 years represent an inadequate monitoring frequency; PSA and testosterone should be measured every 3 to 6 months, and DEXA should be performed at baseline and annually in men on continuous ADT.
Option E: Option E is incorrect because metabolic and bone monitoring during ADT is an integral part of oncology care for prostate cancer and should not be deferred to primary care; the oncology team prescribing ADT is responsible for monitoring and managing its adverse effects, in collaboration with other providers.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.